Barclays Maintains Overweight on CytomX Therapeutics, Raises Price Target to $10
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from $8 to $10.
Barclays analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from $8 to $10.